egfr breast cancer

Release time ：Dec-17,2024

The Epidermal Growth Factor Receptor (EGFR) is a protein present on the surface of many cells and plays a role in controlling cell growth and division. In breast cancer, the overexpression of EGFR is linked to tumor growth and progression. Breast cancers that are EGFR-positive often respond well to certain targeted therapies.

The treatment strategies for EGFR-positive breast cancer primarily encompass chemotherapy, hormonal therapy, and targeted therapy. Chemotherapy works by using drugs to eliminate rapidly dividing cancer cells, thereby controlling cancer progression. Hormonal therapy is mainly used for hormone receptor-positive breast cancers and functions by blocking the effects of estrogen or by reducing estrogen levels in the body to inhibit tumor growth. Targeted therapy is a crucial approach for EGFR-positive breast cancer, where drugs specifically bind to EGFR, halting its signal transduction pathways, which in turn suppresses the growth and spread of tumor cells.

For individuals with EGFR-positive breast cancer, it is advised to select a personalized treatment plan under the guidance of a qualified physician. Regular follow-ups and monitoring are essential to adjust the treatment plan promptly. Throughout the treatment, patients should maintain a positive attitude and actively collaborate with their healthcare providers to enhance treatment outcomes and overall quality of life.